• SPX
  • $5,544.59
  • -0.78 %
  • -$43.68
  • DJI
  • $40,665.02
  • -1.29 %
  • -$533.08
  • N225
  • $39,902.66
  • -0.56 %
  • -$223.47
  • FTSE
  • $8,204.89
  • 0.21 %
  • $17.43
  • IXIC
  • $17,871.22
  • -0.7 %
  • -$125.70

Kronos Bio, Inc. (KRON) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.33

-$0.08

(-5.71%)

Day's range
$1.31
$1.44
52 wk range
$0.69
$2.22
50-day range
$0.69
$1.6
  • Country: US
  • ISIN: US50107A1043
KRON Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -4.11
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (KRON)
  • Company Kronos Bio, Inc.
  • Price $1.33
  • Changes Percentage (-5.71%)
  • Change -$0.08
  • Day Low $1.31
  • Day High $1.44
  • Year High $2.22

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 08/06/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $7.63
  • High Stock Price Target $13.00
  • Low Stock Price Target $2.25
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.99
  • Trailing P/E Ratio -0.37
  • Forward P/E Ratio -0.37
  • P/E Growth -0.37
  • Net Income $-112,673,000

Income Statement

Quarterly

Annual

Latest news of KRON

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Log In


or

Continue with Google Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.